https://doi.org/10.4081/hmr.v3i3.560

The role of maintenance treatment in myeloma

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 155
PDF: 181
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Attal
support@pagepress.org
Autologous stem cell transplantation (ASCT) is now recommended for young patients as part of the initial therapy or at time of the disease progression. However, almost all patients ultimately relapse and the median duration of response after ASCT does not exceed 3 years. To prolong the duration of response, maintenance therapy was a logical approach. The impact of chemotherapy as maintenance after ASCT has never been demonstrated by a randomized trial. In the eighties it was hoped that alpha interferon which prolonged remission duration after conventional chemotherapy could be even more effective in the context of HDT since the tumor burden was lower. Although the preliminary results of a small randomized study were in favour of interferon maintenance after ASCT, the differences with longer follow-up were no longer significant. The end of the story came with the results of the US Intergroup study which failed to show any difference in PFS and OS between interferon and no further treatment in 242 patients responding to either conventional chemotherapy or to ASCT.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Attal, M. (2009). The role of maintenance treatment in myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.560
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).